Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
Eli Lilly (LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...